These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9217779)

  • 21. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting.
    Bonangelino P; Irony T; Liang S; Li X; Mukhi V; Ruan S; Xu Y; Yang X; Wang C
    J Biopharm Stat; 2011 Sep; 21(5):938-53. PubMed ID: 21830924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantifying and documenting prior beliefs in clinical trials.
    Chaloner K; Rhame FS
    Stat Med; 2001 Feb; 20(4):581-600. PubMed ID: 11223902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bayesian stopping rules for trials.
    Kulvichit K
    Lancet; 2002 Jan; 359(9300):77. PubMed ID: 11809215
    [No Abstract]   [Full Text] [Related]  

  • 25. Medicine. Placebo-controls in short-term clinical trials of hypertension.
    Al-Khatib SM; Califf RM; Hasselblad V; Alexander JH; McCrory DC; Sugarman J
    Science; 2001 Jun; 292(5524):2013-5. PubMed ID: 11408643
    [No Abstract]   [Full Text] [Related]  

  • 26. Bayesian stopping rules for trials.
    Nicholl J; Goodacre S
    Lancet; 2002 Jan; 359(9300):76-7. PubMed ID: 11809213
    [No Abstract]   [Full Text] [Related]  

  • 27. Practical Bayesian design and analysis for drug and device clinical trials.
    Hobbs BP; Carlin BP
    J Biopharm Stat; 2008; 18(1):54-80. PubMed ID: 18161542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials.
    Diamond GA; Kaul S
    J Am Coll Cardiol; 2004 Jun; 43(11):1929-39. PubMed ID: 15172393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive trial design.
    Berry DA
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):522-4. PubMed ID: 17679925
    [No Abstract]   [Full Text] [Related]  

  • 30. An orwellian discourse on the meaning and measurement of noninferiority.
    Diamond GA; Kaul S
    Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian methods for design and analysis of safety trials.
    Price KL; Xia HA; Lakshminarayanan M; Madigan D; Manner D; Scott J; Stamey JD; Thompson L
    Pharm Stat; 2014; 13(1):13-24. PubMed ID: 23897858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Believability of clinical trials: a diagnostic testing perspective.
    Lauer MS
    J Thorac Cardiovasc Surg; 2006 Aug; 132(2):249-51. PubMed ID: 16872945
    [No Abstract]   [Full Text] [Related]  

  • 33. n-of-1 trials and their combination: suitable approaches for CAM research?
    Hart A; Sutton CJ
    Complement Ther Med; 2003 Dec; 11(4):213-4. PubMed ID: 14969791
    [No Abstract]   [Full Text] [Related]  

  • 34. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classic or Bayesian research design and analysis. Does it make a difference?
    Bloom BS; de Pouvourville N; Libert S
    Int J Technol Assess Health Care; 2002; 18(1):120-6. PubMed ID: 11987435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New designs for clinical trials.
    Mélot C
    Crit Care Med; 2009 Jan; 37(1 Suppl):S59-64. PubMed ID: 19104226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian adaptive D-optimal design with delayed responses.
    Li J; Fu H
    J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting event times in clinical trials when treatment arm is masked.
    Donovan JM; Elliott MR; Heitjan DF
    J Biopharm Stat; 2006 May; 16(3):343-56. PubMed ID: 16724489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ethics review and clinical trials.
    Ellis SJ
    Lancet; 1998 Apr; 351(9108):1066. PubMed ID: 9546545
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.